Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study.
The lancet oncology.
Times cited: 114
Multiple myeloma is universally preceded by a prolonged premalignant stage: Novel clinical insights and future directions.
Times cited: 2
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
British Journal of Haematology.
Times cited: 61